– CANADA, Montreal – Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors, bringing invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.
About Byron Hewett
Mr. Hewett has more than 30 years of experience leading the development and commercialization of research and diagnostic tools. Most recently, he was CEO and Co-founder at Brava Diagnostics, focusing on point-of-care diagnostics. Previously, he was CEO of SomaLogic, a publicly listed proteomics company, and Chairman and CEO of BioBehavioral Diagnostics, respectively. He was also CEO at Immunicon and held senior roles at Qiagen, Bayer Diagnostics, and Chiron Diagnostics.
“I have been following the progress of Nomic Bio for several years now, and I’ve been quite impressed,” said Byron Hewett. “Nomic’s nELISA platform addresses several of the industry’s bottlenecks in a scalable and versatile manner, and I look forward to collaborating with the team as we drive the company’s growth and expand its impact in the industry.”
About Nomic Bio
Nomic Bio is dedicated to making proteomics as accessible as genomics. Leveraging its nELISA platform, the company aims to dramatically accelerate the discovery and development of new drugs and diagnostics. Currently, Nomic Bio offers the most comprehensive inflammatory secretome panel on the market to over 30 pharma and biotechs, and it is continuously expanding its protein content to cover more of the proteome. Nomic Bio is headquartered in Montreal, with additional labs and offices in Boston, and it is backed by top-tier venture capital firms, including Lux Capital, SR One, and Casdin Capital.
For more information: https://nomic.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
